文献速递核素与放射性配体治疗肿瘤 PET/CT

SPECT/CT在转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617治疗早期反应评估中的作用

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
PubMed 文献 · J Nucl Med · 2024-12-03

本研究回顾性纳入66例接受至少2次177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,评估第2、3周期开始时SPECT/CT测量的总肿瘤体积和新发病灶与后续PSA进展无生存期和总生存期的关联。结果显示较高的总肿瘤体积和新发病灶出现与较差的PSA进展无生存期和总生存期独立相关,且不依赖于PSA变化。

要点

  • 第2、3周期开始时较高的总肿瘤体积与较差的PSA进展无生存期和总生存期独立相关。
  • 第2、3周期开始时出现新发病灶与较差的总生存期独立相关。
  • 总肿瘤体积和新发病灶提供的预后信息独立于PSA变化。

核心结论

  • 第2和第3周期开始时LuPSMA SPECT/CT上较高的总肿瘤体积和新发病灶与较高的死亡风险独立相关。
  • 这些指标提供了独立于PSA变化的预后信息。
  • 有必要开发包含总肿瘤体积、新发病灶和PSA变化的预后和预测模型。

研究设计与样本

  • 回顾性分析2022年6月至12月连续纳入的转移性去势抵抗性前列腺癌患者,均接受至少2次177Lu-PSMA-617治疗并在治疗后24小时行SPECT/CT。
  • 共纳入66例患者,中位年龄74岁,接受中位4个周期(四分位距3-5)的177Lu-PSMA-617治疗。
  • 采用多变量Cox回归评估第2和第3周期总肿瘤体积和新发病灶与后续PSA进展无生存期和总生存期的关联,所有分析均校正PSA水平相对基线的变化。

主要发现

  • 从第2周期开始的中位随访时间为42周(四分位距33-48周),66例患者中24例在分析时已死亡。
  • 第2和第3周期开始时总肿瘤体积相对基线的变化与相应PSA水平变化显著相关(r=0.55和0.56),但绝对总肿瘤体积与PSA无显著相关(r=0.00和0.18)。
  • 第2周期开始时绝对总肿瘤体积较高的患者PSA进展无生存期和总生存期较差(风险比[HR]1.4[95%CI 1.1-1.8]和2.1[95%CI 1.5-2.9]),第3周期开始时结果一致(HR 2[95%CI 1.4-2.9]和2[95%CI 1.2-3.2])。
  • 第2和第3周期开始时分别有13/66和11/51例患者发现新发病灶;第2周期开始时新发病灶与较差的总生存期相关(HR 5.8[95%CI 1.9-17.5]),第3周期开始时结果一致(HR 4.9[95%CI 1.3-18.6])。
  • 多变量分析中,第2和第3周期开始时较高的总肿瘤体积和新发病灶出现与较差的总生存期独立相关。

关键数值与推荐

  • 第2周期开始时较高绝对总肿瘤体积:PSA进展无生存期HR 1.4(95%CI 1.1-1.8),总生存期HR 2.1(95%CI 1.5-2.9)。
  • 第3周期开始时较高绝对总肿瘤体积:PSA进展无生存期HR 2(95%CI 1.4-2.9),总生存期HR 2(95%CI 1.2-3.2)。
  • 第2周期开始时新发病灶:总生存期HR 5.8(95%CI 1.9-17.5)。
  • 第3周期开始时新发病灶:总生存期HR 4.9(95%CI 1.3-18.6)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated the role of total tumor volumes (TTVs) and new lesions (NLs) determined by LuPSMA SPECT/CT in early cycles to predict subsequent outcomes in a real-world practice setting. Methods: Between June and December 2022, consecutive patients with mCRPC who received at least 2 administrations of LuPSMA with SPECT/CT 24 h after treatment were retrospectively reviewed. We evaluated associations between TTVs and the appearance of NLs at cycles 2 and 3 with subsequent prostate-specific antigen (PSA) progression-free survival and overall survival (OS) using multivariate Cox regression. All analyses were adjusted for changes in PSA level relative to baseline. Results: Sixty-six mCRPC patients (median age, 74 y) received a median of 4 (interquartile range, 3-5) cycles of LuPSMA. Median follow-up starting at cycle 2 was 42 wk (interquartile range, 33-48 wk), with 24 of 66 patients deceased at the time of the analysis. Changes in TTV measured at the start of cycles 2 and 3 relative to baseline correlated significantly with corresponding changes in PSA level (r = 0.55 and 0.56), but absolute TTVs did not correlate significantly (r = 0.00 and 0.18). Patients with a higher absolute TTV at the start of cycle 2 had worse PSA progression-free survival and OS (hazard ratio [HR], 1.4 [95% CI, 1.1-1.8] and 2.1 [95% CI, 1.5-2.9]), with consistent results at the start of cycle 3 (HR, 2 [95% CI, 1.4-2.9] and 2 [95% CI, 1.2-3.2]). NLs were identified in 13 of 66 and 11 of 51 patients at the start of cycles 2 and 3. NLs at the start of cycle 2 were associated with worse OS (HR, 5.8 [95% CI, 1.9-17.5]), with consistent results at the start of cycle 3 (HR, 4.9 [95% CI, 1.3-18.6]). In multivariate analysis, a higher TTV and the appearance of NLs at the start of cycles 2 and 3 were independently associated with poorer OS. Conclusion: Higher TTVs and NLs on LuPSMA SPECT/CT at the start of cycles 2 and 3 were independently associated with higher risk of death. These measures provided prognostic information independent of changes in PSA. Development of prognostic and predictive models including TTV, NLs, and PSA changes is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Demirci RA, Gulati R, Hawley JE, et al. SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617. J Nucl Med. 2024. PMID: 39510589. doi:10.2967/jnumed.124.267665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。